“The present predicament has exposed some structural weaknesses in the EU’s medicines offer chain in addition to a large dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides reported. She recommended that provide chain difficulties be resolved within an EU pharmaceutical tactic predicted to be launched by the end of